Akero Therapeutics Inc’s filing revealed that its President and CEO Cheng Andrew unloaded Company’s shares for reported $1.58 million on Feb 10 ’25. In the deal valued at $52.73 per share,30,000 shares were sold. As a result of this transaction, Cheng Andrew now holds 686,062 shares worth roughly $ 33.92 million.
Then, Graham G. Walmsley bought 200,000 shares, generating $9,600,000 in total proceeds. Upon buying the shares at $48.00, the Director now owns 1,000,000 shares.
Before that, Rolph Timothy sold 18,750 shares. Akero Therapeutics Inc shares valued at $1,059,630 were divested by the Chief Scientific Officer at a price of $56.51 per share. As a result of the transaction, Rolph Timothy now holds 170,237 shares, worth roughly $8.42 million.
BofA Securities upgraded its Akero Therapeutics Inc [AKRO] rating to a Buy from a a Neutral in a research note published on January 30, 2025; the price target was increased to $63 from $35. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in late January has reiterated a ‘”a Buy”‘ rating for it. Citigroup began covering AKRO with “Buy” recommendation on November 18, 2024.
Price Performance Review of AKRO
On Tuesday, Akero Therapeutics Inc [NASDAQ:AKRO] saw its stock fall -2.14% to $49.44. Over the last five days, the stock has lost -3.34%. Akero Therapeutics Inc shares have risen nearly 77.71% since the year began. Nevertheless, the stocks have risen 127.31% over the past one year. While a 52-week high of $58.40 was reached on 01/27/25, a 52-week low of $17.86 was recorded on 01/14/25. SMA at 50 days reached $35.63, while 200 days put it at $28.51.
Levels Of Support And Resistance For AKRO Stock
The 24-hour chart illustrates a support level at 48.73, which if violated will result in even more drops to 48.01. On the upside, there is a resistance level at 50.77. A further resistance level may holdings at 52.10. The Relative Strength Index (RSI) on the 14-day chart is 61.46, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.14, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 90.55%. Stochastics %K at 17.26% indicates the stock is a buying.
The most recent change occurred on September 19, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $69 price target.
